Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
Date:3/10/2012

in royalty revenues was in line with our expectations and results from a decline in sales of Thalomid® in the United States.  We will continue to carefully monitor and control expenses and deploy capital in strategic ways."  Further up-to-date information regarding the Company, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, can be found on our web site at www.entremed.com.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently completing a multi-center Phase 2 study in ovarian cancer and completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expect
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
2. EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results
3. EntreMed Reports Receipt of Third Quarter Royalty Payment
4. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
5. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
6. EntreMed to Present at the New York Society of Security Analysts Industry Conference
7. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
8. EntreMed Reports Third Quarter 2008 Financial Results
9. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
10. EntreMed to Present at BioPartnering Europe Conference
11. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... LYNBROOK, N.Y. , Aug. 21, 2014 /PRNewswire/ ... a biopharmaceutical company developing first in class collagenase-based ... histolyticum or CCH) in the U.S. and XIAPEX ... statistically significant results from a randomized, double-blind Phase ... of cellulite, or edematous fibrosclerotic panniculopathy. The results ...
(Date:8/21/2014)... has observed tiny quantum vortices in cold droplets of ... Science that the exotic vortices arrange themselves as ... first time that the quantum vortices, which have already ... as superfluid helium, have been detected in nanodroplets. "The ... of the University of Southern California, one of the ...
(Date:8/21/2014)... Emmetsburg, IA (PRWEB) August 21, 2014 ... Project LIBERTY Opening , The Court of His Majesty ... King will attend the Grand Opening of POET-DSM Advanced ... on Wednesday, Sept. 3. , The King will take ... formal opening activity, scheduled for 11 a.m.-12:20 p.m. and ...
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... and Mexico ... several newly approved agents, the anticipated label extension ... the launch of emerging biologics will substantially increase ... the emerging IL-5 inhibitors will introduce a new dynamic ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... Editor's note: This is the second of a two-part opinion piece ... M adison, Wis. - The environmental ... evidence that ethanol increases nitrous oxides and ozone. These studies were ... Environmental Protection Agency , the California Air Resources Board ...
... - NimbleGen Systems, Inc. , a supplier ... new chief financial officer with experience managing large entrepreneurial ... years of experience in capital raising, finance, and general ... estate, and diversified manufacturing. , ,In a statement released ...
... Wisconsin Department of Agriculture, Trade and Consumer Protection ... University of Wisconsin-Milwaukee for research on sustainable and ... , ,The research project, headed by Sarah Gong, ... to strengthen the state's plastics industry and encourage technology ...
Cached Biology Technology:Last ethanol article you'll ever need to read, Part II 2Last ethanol article you'll ever need to read, Part II 3Last ethanol article you'll ever need to read, Part II 4NimbleGen names CFO with capital-raising past 2UWM receives state funding for plastics research 2
(Date:8/21/2014)... smog-producing toxins in past decade, GTA still violates ... that while the Greater Toronto Area (GTA) has ... to smog, the city continues to violate the ... can cause or aggravate health problems such as ... a set of complex photochemical reactions involving volatile ...
(Date:8/21/2014)... fungus linked to dandruff, eczema and other itchy, flaky ... further global reachesincluding Hawaiian coral reefs and the extreme ... A review in the scientific journal PLOS Pathogens ... fungi of the genus Malassezia in light ... from around the world. , University of Hawai,i at ...
(Date:8/21/2014)... the Fram Strait is a key region in the global ... Greenland and Svalbard warm Atlantic water flows to the north ... Arctic water masses and sea ice push their way out ... of the Atlantic water cools here on its way to ... the water caused in this manner drives the global band ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
... children living in communities where they do not receive ... given supplements, even if they are HIV-infected, according to ... Health and other institutions. , Previously, it was not ... in children by increasing their viral load. Zinc supplementation ...
... Many baffled parents have wondered whether their teenagers would ... have never really quite understood just how an organism ... growth should cease. , Now University of Washington biologists ... fly, have discovered an organ that assesses the size ...
... provides definitive answers and ways to repair lives , A ... of radiation exposure from the Chernobyl nuclear power plant (NPP) ... than 100 scientists has concluded. , As of mid-2005, however, ... from the disaster, almost all being highly exposed rescue workers, ...
Cached Biology News:Zinc supplements safe for HIV-infected children 2Researchers find gland that tells fruit flies when to stop growing 2Researchers find gland that tells fruit flies when to stop growing 3Chernobyl: The true scale of the accident 2Chernobyl: The true scale of the accident 3Chernobyl: The true scale of the accident 4Chernobyl: The true scale of the accident 5Chernobyl: The true scale of the accident 6Chernobyl: The true scale of the accident 7Chernobyl: The true scale of the accident 8Chernobyl: The true scale of the accident 9Chernobyl: The true scale of the accident 10Chernobyl: The true scale of the accident 11Chernobyl: The true scale of the accident 12Chernobyl: The true scale of the accident 13Chernobyl: The true scale of the accident 14Chernobyl: The true scale of the accident 15Chernobyl: The true scale of the accident 16
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
... Object Parametric Analyzer and Sorter) large particle ... advantages of flow cytometry to applications that ... automated analysis and sorting. Our instruments ... traditional flow cytometers, but are designed to ...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
... raised against a partial recombinant ... SF3B2 (NP_006833, 592 a.a. ... protein with GST tag. ... NM_006842 Protein ...
Biology Products: